^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alomfilimab (SAR445256)

    i
    Other names: SAR445256, KY1044, KY 1044
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    ICOS agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. (PubMed, J Immunother Cancer)
    Alomfilimab treatment was associated with an acceptable safety profile across both mono and combination approaches, accompanied by decreased ICOS+Tregs populations and enhanced CD4+ and CD8+ effector T cells cell activity. Limited clinical activity was observed despite evidence of biological activity.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    over1year
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=222, Terminated, Kymab Limited | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
    Trial termination • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    2years
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    over2years
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Trial completion date: Nov 2024 --> Apr 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    almost3years
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    over3years
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Kymab Limited | N=412 --> 280 | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: May 2023 --> Nov 2024
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)